Blood Pressure Management in High-Risk Patients
Introduction to Blood Pressure Targets
- The American College of Cardiology recommends a blood pressure target of <130/80 mmHg for patients with diabetes and hypertension, representing a balance between cardiovascular benefit and risk of adverse events 2, 3
Key Findings on Intensive Treatment
- Intensive blood pressure treatment targeting systolic blood pressure <120 mmHg significantly reduces cardiovascular events by 25% compared to standard treatment targeting <140 mmHg, though with increased risk of adverse events 1, 2
- The SPRINT trial, which enrolled 9,361 patients with systolic blood pressure ≥130 mmHg and increased cardiovascular risk, demonstrated a 25% reduction in the composite outcome of myocardial infarction, coronary syndromes, stroke, heart failure, or cardiovascular death in the intensive treatment group 1
Comparison with Other Trials
- The ACCORD BP trial specifically studied patients with type 2 diabetes and demonstrated a significant 41% reduction in stroke in the intensive treatment group, although it did not show a statistically significant reduction in the primary composite cardiovascular endpoint 1, 2
Adverse Events Associated with Intensive Treatment
- The intensive treatment arm experienced more adverse events, including hypotension, syncope, electrolyte abnormalities, acute kidney injury, bradycardia, hyperkalemia, and elevations in serum creatinine 1, 2, 3
Clinical Implications and Guidelines
- Current guidelines recommend individualized blood pressure targets through shared decision-making that considers cardiovascular risk, potential adverse effects, and patient preferences 2
- The American College of Cardiology suggests that treatment should not aim for blood pressure <120/80 mmHg as a mean achieved blood pressure below this threshold is associated with increased adverse events 2